Fact CheckerSign in

NCT07573826Not yet recruiting

Effect of Pursed-Lip Breathing With Different I:E Ratios on Respiratory Outcomes in COPD Patients

Effectiveness of Different Inspiratory-Expiratory Ratios (1:3, 1:4, and 1:5) in Pursed-Lip Breathing on Respiratory Rate, Oxygen Saturation, and Dyspnea in Patients With Chronic Obstructive Pulmonary Disease: A Quasi-Experimental Study

Source: ClinicalTrials.gov · Last updated 7 May 2026

Brief summary (registry, in English)

The goal of this clinical trial is to evaluate whether different inspiratory-expiratory (I:E) ratios in the pursed-lip breathing (PLB) technique can improve respiratory outcomes in patients with stable Chronic Obstructive Pulmonary Disease (COPD) aged 40 years and older. The primary purpose is to determine whether a specific breathing intervention can improve respiratory function. The main questions it aims to answer are: Does PLB with different I:E ratios (1:3, 1:4, and 1:5) reduce respiratory rate in COPD patients? Does PLB with different I:E ratios improve oxygen saturation and reduce dyspnea severity? Researchers will compare PLB with I:E ratios of 1:3, 1:4, and 1:5 and a control group receiving standard care to see if different ratios produce different effects on respiratory rate, oxygen saturation, and dyspnea levels. Participants will: Perform pursed-lip breathing using assigned I:E ratios (1:3, 1:4, or 1:5) for 10 minutes Be assigned to either an intervention group or a control group (standard care) Have their respiratory rate measured before and after the intervention Have their oxygen saturation measured using a pulse oximeter Report their dyspnea level using the Modified Borg Scale before and after the intervention

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
122 (estimated)
First submitted
30 Apr 2026
Start date
4 May 2026
Primary completion date
7 Aug 2026
Lead sponsor
Scholastica Fina Aryu Puspasari
Diseases
COPD
NCT number
NCT07573826

What you commit to

  • Study type: Interventional
  • Planned participants: 122
  • From 4 May 2026 to the primary completion date, 7 Aug 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Cognitive impairment or decreased consciousness
  • Severe cardiovascular disease (heart failure, coronary artery disease, pulmonary hypertension)
  • Acute respiratory infection (e.g., pneumonia)
  • Neuromuscular disorders affecting respiratory muscles

Other

  • Asthma-COPD overlap (ACO)

Who the study is looking for

  • Diagnosed with stable COPD
  • Age ≥ 40 years
  • Able to follow breathing instructions
  • Willing to participate and provide informed consent

Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.